In particular, the role of EZH2 in prostate cancer is multi-faceted, in that it can both promote and repress AR transcriptional activity during CRPC and in response to ARSI respectively, depending on the specific subunits it adopts and the cofactors that it interacts with. Here, AR is linked to prostate cancer.